From: Emerging markers of cachexia predict survival in cancer patients
Parameters | Cancer group | HS group | Follow up (18 months) | ||
---|---|---|---|---|---|
Death | Survivors | P | |||
n:140 | n: 30 | n:94 (67%) | n:46 (33%) | ||
Age, y | 61.8 ± 14.3 | 59.6 ± 12.2 | 67.4 ± 6.3 | 60.7 ± 8.9 | 0.01 |
Weight change, % | 12.1 ± 8.9 | - | 18.6 ± 1.8 | 7.6 ± 2.3 | < 0.0001 |
Tot cholesterol (mg/dL) | 142.9 ± 27.2 | 175.6 ± 12.6 | 139.6 ± 9.6 | 141.6 ± 10.6 | 0.23 |
Diabetics, n | 28 (20%) | - | 18 | 10 | 0.10* |
Hypertension, n | 52 (37%) | - | 30 | 22 | 0.19* |
Heart Failure, n | 16 (11%) | - | 10 | 6 | 0.29* |
CKD, n | 56 (40%) | - | 37 | 19 | 0.003 |
Hemoglobin, g/dl | 10.1 ± 2.5 | 13.6 ± 1.7 | 9.3 ± 1.6 | 10.8 ± 1.8 | < 0.0001 |
Metastatic disease, n | 105 (75%) | - | 90 | 15 | <0.0001* |
Albumin, g/L | 2.7 ± 0.6 | 4.02 ± 0.8 | 2.3 ± 0.4 | 2.5 ± 0.5 | 0.004 |
Obestatin, ng/ml | 17.4 ± 7.1 | 24.8 ± 5.5 | 12.3 ± 2 | 15.1 ± 4.8 | 0.005 |
Leptin, ng/ml | 38.4 ± 21.2 | 76.2 ± 17.4 | 21.8 ± 10 | 33.8 ± 9.1 | < 0.0001 |
Ghrelin ng/ml | 573.3 ± 130 | 320.2 ± 66.8 | 657.6 ± 88 | 481.4 ± 43.6 | < 0.0001 |